


## BTK inhibitor 10

Cat. No.:	HY-125997
CAS No.:	2241732-30-7
Molecular Formula:	C <sub>25</sub> H <sub>23</sub> N <sub>5</sub> O <sub>3</sub>
Molecular Weight:	441.48
Target:	Btk
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : Bruton kinase (BTK) <sup>[1]</sup>								
<b>In Vivo</b>	<p>BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days' oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>DBA/1J mice injected with collagen as a CIA model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>oral gavage; 21 days; once daily</td> </tr> <tr> <td>Result:</td> <td>Decreased arthritis scores significantly when it compares to control group.</td> </tr> </table>	Animal Model:	DBA/1J mice injected with collagen as a CIA model <sup>[1]</sup>	Dosage:	30 mg/kg	Administration:	oral gavage; 21 days; once daily	Result:	Decreased arthritis scores significantly when it compares to control group.
Animal Model:	DBA/1J mice injected with collagen as a CIA model <sup>[1]</sup>								
Dosage:	30 mg/kg								
Administration:	oral gavage; 21 days; once daily								
Result:	Decreased arthritis scores significantly when it compares to control group.								

### REFERENCES

[1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA